Biomea Fusion presents COVALENT-111 data: up to 1.4% placebo-adjusted HbA1c reduction at Week 26 off therapy

Biomea Fusion, Inc.

Placebo-adjusted mean HbA1c reduction up to 1.4% at Week 26 after 28-day BMF-219 treatment.
100mg and 200mg dose levels selected for expansion phase; 12-week dosing, follow-up to Week 52.
No serious adverse events or study discontinuations; no symptomatic hypoglycemia.
Expansion phase enrolling on schedule; initial 26-week data expected 2H24.
Biomea plans to announce COVALENT-112 T1D update in Q4 2023 earnings release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.